Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorLIMA, Glauce L.
dc.contributor.authorPAUPITZ, Juliane
dc.contributor.authorAIKAWA, Nadia E.
dc.contributor.authorTAKAYAMA, Liliam
dc.contributor.authorBONFA, Eloisa
dc.contributor.authorPEREIRA, Rosa M. R.
dc.date.accessioned2016-03-14T14:21:54Z
dc.date.available2016-03-14T14:21:54Z
dc.date.issued2016
dc.description.abstractObjective. Vitamin D has an important immunomodulatory effect, but there are no trials that directly address the boosting of serum levels of 25-hydroxyvitamin D (25[ OH] D) in juvenile-onset systemic lupus erythematosus (SLE). The aim of this study was to evaluate the effect of vitamin D supplementation on disease activity and fatigue in juvenile-onset SLE. Methods. This study was a randomized, double-blind, placebo-controlled, 24-week trial. Forty juvenile-onset SLE patients were randomized (1: 1) to receive oral cholecalciferol 50,000 IU/week (juvenile-onset SLE-VitD) or placebo (juvenile-onset SLE-PL). Medications remained stable throughout the study. Serum levels of 25(OH) D were measured using radioimmunoassay. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the European Consensus Lupus Activity Measurement (ECLAM). Fatigue was assessed using the Kids Fatigue Severity Scale (K-FSS). Results. At baseline, groups were similar regarding age, body mass index, organ involvement, glucocorticoid dose, use of immunosuppressive drugs, SLEDAI, ECLAM, K-FSS, and levels of 25(OH) D. After 24 weeks, the mean level of 25(OH) D was higher in the juvenile-onset SLE-VitD group than in the juvenile-onset SLE-PL group (P < 0.001). At the end of the intervention, a significant improvement in SLEDAI (P = 0.010) and in ECLAM (P = 0.006) was observed in the juvenile-onset SLE-VitD group compared to the juvenile-onset SLE-PL group. Regarding fatigue evaluation, a reduction of fatigue related to social life score was found in the juvenile-onset SLE-VitD group compared to the juvenile-onset SLE-PL group (P = 0.008). Cholecalciferol was well tolerated with no serious adverse events. Conclusion. This study suggests that cholecalciferol supplementation for 24 weeks is effective in decreasing disease activity and improving fatigue in juvenile-onset SLE patients.
dc.description.indexMEDLINE
dc.description.sponsorshipCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [301411/2009-3, 301805/2013-0, 472754/2013-0]
dc.description.sponsorshipFederico Foundation
dc.identifier.citationARTHRITIS CARE & RESEARCH, v.68, n.1, p.91-98, 2016
dc.identifier.doi10.1002/acr.22621
dc.identifier.eissn2151-4658
dc.identifier.issn2151-464X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/13387
dc.language.isoeng
dc.publisherWILEY-BLACKWELL
dc.relation.ispartofArthritis Care & Research
dc.rightsrestrictedAccess
dc.rights.holderCopyright WILEY-BLACKWELL
dc.subject.otherquality-of-life
dc.subject.otherd deficiency
dc.subject.othermultiple-sclerosis
dc.subject.otherrheumatic-diseases
dc.subject.otheractivity index
dc.subject.otherassociation
dc.subject.otherrisk
dc.subject.otherprevalence
dc.subject.otherautoimmunity
dc.subject.otherprotein
dc.subject.wosRheumatology
dc.titleVitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus111
hcfmusp.contributor.author-fmusphcGLAUCE LEAO LIMA
hcfmusp.contributor.author-fmusphcJULIANE ALINE PAUPITZ
hcfmusp.contributor.author-fmusphcNADIA EMI AIKAWA
hcfmusp.contributor.author-fmusphcLILIAM TAKAYAMA GUERRA
hcfmusp.contributor.author-fmusphcELOISA SILVA DUTRA DE OLIVEIRA BONFA
hcfmusp.contributor.author-fmusphcROSA MARIA RODRIGUES PEREIRA
hcfmusp.description.beginpage91
hcfmusp.description.endpage98
hcfmusp.description.issue1
hcfmusp.description.volume68
hcfmusp.origemWOS
hcfmusp.origem.pubmed25988278
hcfmusp.origem.scopus2-s2.0-84956646097
hcfmusp.origem.wosWOS:000367682800010
hcfmusp.publisher.cityHOBOKEN
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAmital H, 2010, ANN RHEUM DIS, V69, P155
hcfmusp.relation.referenceWYSENBEEK AJ, 1993, BRIT J RHEUMATOL, V32, P633
hcfmusp.relation.referenceHypponen E, 2010, DIABETES OBES METAB, V12, P737, DOI 10.1111/j.1463-1326.2010.01211.x
hcfmusp.relation.referencede Borst MH, 2011, CURR DRUG TARGETS, V12, P97
hcfmusp.relation.referenceKRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121
hcfmusp.relation.referenceSchmeding A, 2013, BEST PRACT RES CL RH, V27, P363, DOI 10.1016/j.berh.2013.07.009
hcfmusp.relation.referenceRuiz-Irastorza G, 2010, ARTHRIT CARE RES, V62, P1160, DOI 10.1002/acr.20186
hcfmusp.relation.referenceWright TB, 2009, J PEDIATR-US, V155, P260, DOI 10.1016/j.jpeds.2009.02.033
hcfmusp.relation.referenceYang CY, 2013, CLIN REV ALLERG IMMU, V45, P217, DOI 10.1007/s12016-013-8361-3
hcfmusp.relation.referenceAbou-Raya A, 2013, J RHEUMATOL, V40, P265, DOI 10.3899/jrheum.111594
hcfmusp.relation.referenceHochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928
hcfmusp.relation.referenceSahebari M, 2014, LUPUS, V23, P1164, DOI 10.1177/0961203314540966
hcfmusp.relation.referenceBirmingham DJ, 2012, LUPUS, V21, P855, DOI 10.1177/0961203312439640
hcfmusp.relation.referenceCasella CB, 2012, LUPUS, V21, P1335, DOI 10.1177/0961203312454929
hcfmusp.relation.referenceFuchs SC, 2002, BMC PUBLIC HEALTH, V2, DOI 10.1186/1471-2458-2-1
hcfmusp.relation.referenceBOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606
hcfmusp.relation.referenceKiani AN, 2013, RHEUMATOLOGY, V52, P2071, DOI 10.1093/rheumatology/ket271
hcfmusp.relation.referenceCutolo M, 2009, ANN RHEUM DIS, V68, P446, DOI 10.1136/ard.2008.093476
hcfmusp.relation.referenceStockton KA, 2012, LUPUS, V21, P271, DOI 10.1177/0961203311425530
hcfmusp.relation.referencePeracchi OAB, 2014, BRAZ J MED BIOL RES, V47, P721, DOI 10.1590/1414-431X20143948
hcfmusp.relation.referenceAntico A, 2012, AUTOIMMUN REV, V12, P127, DOI 10.1016/j.autrev.2012.07.007
hcfmusp.relation.referenceCutolo M, 2008, LUPUS, V17, P6, DOI 10.1177/0961203307085879
hcfmusp.relation.referenceMunger KL, 2006, JAMA-J AM MED ASSOC, V296, P2832, DOI 10.1001/jama.296.23.2832
hcfmusp.relation.referenceGatenby P, 2013, CURR OPIN RHEUMATOL, V25, P184, DOI 10.1097/BOR.0b013e32835cfc16
hcfmusp.relation.referenceBonakdar ZS, 2011, LUPUS, V20, P1155, DOI 10.1177/0961203311405703
hcfmusp.relation.referenceCanalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198-007-0394-0
hcfmusp.relation.referenceRuiz-Irastorza G, 2008, RHEUMATOLOGY, V47, P920, DOI 10.1093/rheumatology/ken121
hcfmusp.relation.referenceHolick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385
hcfmusp.relation.referenceRitterhouse LL, 2011, ANN RHEUM DIS, V70, P1569, DOI 10.1136/ard.2010.148494
hcfmusp.relation.referenceTench CM, 2000, RHEUMATOLOGY, V39, P1249, DOI 10.1093/rheumatology/39.11.1249
hcfmusp.relation.referenceKamen D, 2008, CURR OPIN RHEUMATOL, V20, P532, DOI 10.1097/BOR.0b013e32830a991b
hcfmusp.relation.referenceArnson Y, 2007, ANN RHEUM DIS, V66, P1137, DOI 10.1136/ard.2007.069831
hcfmusp.relation.referenceBENCIVELLI W, 1992, CLIN EXP RHEUMATOL, V10, P549
hcfmusp.relation.referenceSchneider L, 2014, CLIN RHEUMATOL, V33, P1033, DOI 10.1007/s10067-014-2530-5
hcfmusp.relation.referenceHolick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
hcfmusp.relation.referenceKamen DL, 2006, AUTOIMMUN REV, V5, P114, DOI 10.1016/j.autrev.2005.05.009
hcfmusp.relation.referenceCutolo M, 2009, RHEUMATOLOGY, V48, P210, DOI 10.1093/rheumatology/ken394
hcfmusp.relation.referenceStagi S, 2014, LUPUS, V23, P1059, DOI 10.1177/0961203314532564
hcfmusp.relation.referenceZold E, 2011, VITAM HORM, V86, P261, DOI 10.1016/B978-0-12-386960-9.00011-3
hcfmusp.relation.referenceWortsman J, 2000, AM J CLIN NUTR, V72, P690
hcfmusp.relation.referenceChaiamnuay S, 2013, JCR-J CLIN RHEUMATOL, V19, P121, DOI 10.1097/RHU.0b013e318289bd16
hcfmusp.relation.referenceDeLuca Hector F, 2004, Am J Clin Nutr, V80, p1689S
hcfmusp.relation.referenceHamza RT, 2011, MED SCI MONITOR, V17, P711
hcfmusp.relation.referenceHoughton KM, 2008, ARTHRIT RHEUM-ARTHR, V59, P537, DOI 10.1002/art.23534
hcfmusp.relation.referenceMandal M, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4479
hcfmusp.relation.referencePetri M, 2013, ARTHRITIS RHEUM-US, V65, P1865, DOI 10.1002/art.37953
hcfmusp.relation.referenceRobinson AB, 2014, LUPUS SCI MED, V1, DOI 10.1136/LUPUS-2014-000011
hcfmusp.relation.referenceTerrier B, 2012, ARTHRITIS RES THER, V5, pR221
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication09a6869b-c6d8-4ecd-8a1c-0ec1d0905e4f
relation.isAuthorOfPublicatione2e9bfe9-d926-42c8-8123-b9b3aa703e88
relation.isAuthorOfPublicationd269a535-0477-491e-84b5-73ed38da4033
relation.isAuthorOfPublication304910b3-77c3-4190-bd44-bb12480cd373
relation.isAuthorOfPublication708e64de-56af-4523-b920-b237f71535b2
relation.isAuthorOfPublicationa7d269ab-50f5-415f-a84f-b03f05f2093c
relation.isAuthorOfPublication.latestForDiscovery09a6869b-c6d8-4ecd-8a1c-0ec1d0905e4f
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_DEGASPARE_When_Is_the_Appropriate_Time_for_Pediatric_Acute_2015.PDF
Tamanho:
125.82 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - LIM/36